期刊文献+

贝复舒在膜性结膜炎治疗中的临床应用 被引量:6

Clinical study of Beifushu in the treatment of membranous conjunctivitis
下载PDF
导出
摘要 目的:探讨应用贝复舒治疗膜性结膜炎的方法及效果。方法:选择膜性结膜炎患者52例共90只眼,随机分成两组,实验组45例在使用妥布霉素滴眼液、利巴韦林滴眼液点眼和剥膜治疗的同时加用贝复舒,对照组45例只使用妥布霉素滴眼液、利巴韦林滴眼液点眼和剥膜治疗,两组皆不全身用药。结果:实验组7±0.2d后结膜面无膜形成,结膜面完整,结膜荧光素钠染色阴性,结膜损伤完全修复,结膜轻度充血;对照组14±0.5d后结膜面无膜形成,结膜面完整,结膜荧光素钠染色阴性,结膜损伤完全修复,结膜轻度充血。结论:对膜性结膜炎患者应用贝复舒可明显缩短结膜损伤修复时间,提高疗效。 Objective:To explore the method and effect of application of bFGF in the treatment of membranous conjunctivitis.Methods:Select the membranous conjunctivitis in 52 patients with a total of 90 eyes,and randomly divided into 2groups,the experimental group of 45 eyes in the use of Tobramycin Eye Drops,Ribavirin Eye Drops and stripping treatment,at the same time,use Bei Fushu.45 eyes in the control group only use Tobramycin Eye Drops,Ribavirin Eye Drops and stripping treatment,The 2groups were not systemic medication.Results:Given the conjunctival sac of sodium fluorescein staining test paper dyeing,through the slit lamp examination,after about one week,the conjunctiva of the experimental group without film formation,the surface of the conjunctival was complete,negative staining of conjunctival fluorescein sodium,the conjunctival injury was repaired,mild conjunctival hyperemia;after about two weeks,the conjunctiva of the control group without film formation,the surface of the conjunctival was complete,negative staining of conjunctival fluorescein sodium,the conjunctival injury was repaired,mild conjunctival hyperemia.Conclusion:Using the Bei Fushu,can shorten the repair time of the conjunctival injury and improve the curative effect.
作者 刘彦芳
出处 《陕西医学杂志》 CAS 2015年第2期233-234,共2页 Shaanxi Medical Journal
关键词 结膜炎 细菌性/药物疗法 成纤维细胞生长因子/治疗应用 @贝复舒 Conjunctivitis bacterial/drug therapy Fibroblast growth factors/therapeutic use @Beifushu
  • 相关文献

参考文献2

二级参考文献39

  • 1杨志强,王改霞.羊膜移植治疗义眼座植入术后眼座暴露29例[J].新乡医学院学报,2005,22(4):381-382. 被引量:2
  • 2崔红光,陈艳红,郦惠燕.义眼座植入同期利用羊膜移植结膜囊重建术的临床观察[J].中华眼科杂志,2005,41(11):1005-1008. 被引量:22
  • 3Heilmann, C.A., Attmann, T., von Samson, P., Gobel, H., Marme, D., Beyersdorf, F., Lutter, G., 2003. Transmyocardial laser revascularization combined with vascular endothelial growth factor 121 (VEGF121) gene therapy for chronic myocardial ischemia--do the effects really add up? Eur. J. Cardiothorac. Surg., 23(1):74-80. [doi: 10.1016/S 1010-7940(02)00718-2].
  • 4Henry, T.D., Annex, B.H., McKendall, G.R., Azrin, M.A., Lopez, J.J., Giordano, F.J., Shah, P.K., Willerson, J.T., Benza, R.L., Berman, D.S., et al., 2003. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation, 107(10):1359-1365. [doi 10.1161/01 .CIR.0000061911.47710.8A].
  • 5Henry, T.D., Grines, C.L., Watkins, M.W.,Dib, N., Barbeau, G., Moreadith, R., Andrasfay, T., Engler, R.L., 2007. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J. Am. Coll. Cardiol., 50(11):1038-1046. [doi:10.1016/j.jacc 2007.06.010].
  • 6House, S.L., Bolte, C., Zhou, M., Doetschman, T., Klevitsky, R., Newman, G., Schultz Jel, J., 2003. Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation, 108(25):3140- 3148. [doi:10.1161/01.ClR.0000105723.91637.1C].
  • 7Hughes, G.C., Kypson, A.P., St. Louis, J.D., Annex, B.H., Coleman, R.E., DeGrado, T.R., Donovan, C.L., Lowe, J.E., Landolfo, K.P., 1999. Improved perfusion and contractile reserve after transmyocardial laser revascularization in a model of hibernating myocardium. Ann. Thorac. Surg., 67(6): 1714-1720. [doi: 10.1016/S0003-4975(99)00 317-3].
  • 8Iwakura, A., Fujita, M., Kataoka, K., Tambara, K., Sakakibara, Y., Komeda, M., Tabata, Y., 2003. Intramyocardial sustained delivery of basic fibroblast growth factor improves angiogenesis and ventricular function in a rat infarct model. Heart Vessels, 18(2):93-99.[doi: 10.1007/s10380- 002-0686-5].
  • 9Jeon, O., Ryu, S.H., Chung, J.H., Kim, B.S., 2005. Control of basic fibroblast growth factor release from fibrin gel with heparin and concentrations of fibrinogen and thrombin. J. Control Release, 105(3):249-259. [doi:10.1016/j.jconrel. 2005.03.023].
  • 10Jiang, Z.S., Srisakuldee, W., Soulet, F., Bouche, G., Kardami, E., 2004. Non-angiogenic FGF-2 protects the ischemic heart from injury, in the presence or absence of reperfusion. Cardiovasc. Res., 62(1):154-166. [cloi:10.1016/j. cardiores.2004.01.009].

共引文献16

同被引文献40

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部